The chemiluminescence based Ziplex® automated workstation focus array reproduces ovarian cancer Affymetrix GeneChip® expression profiles

BackgroundAs gene expression signatures may serve as biomarkers, there is a need to develop technologies based on mRNA expression patterns that are adaptable for translational research. Xceed Molecular has recently developed a Ziplex® technology, that can assay for gene expression of a discrete number of genes as a focused array. The present study has evaluated the reproducibility of the Ziplex system as applied to ovarian cancer research of genes shown to exhibit distinct expression profiles initially assessed by Affymetrix GeneChip® analyses.MethodsThe new chemiluminescence-based Ziplex® gene expression array technology was evaluated for the expression of 93 genes selected based on their Affymetrix GeneChip® profiles as applied to ovarian cancer research. Probe design was based on the Affymetrix target sequence that favors the 3' UTR of transcripts in order to maximize reproducibility across platforms. Gene expression analysis was performed using the Ziplex Automated Workstation. Statistical analyses were performed to evaluate reproducibility of both the magnitude of expression and differences between normal and tumor samples by correlation analyses, fold change differences and statistical significance testing.ResultsExpressions of 82 of 93 (88.2%) genes were highly correlated (p < 0.01) in a comparison of the two platforms. Overall, 75 of 93 (80.6%) genes exhibited consistent results in normal versus tumor tissue comparisons for both platforms (p < 0.001). The fold change differences were concordant for 87 of 93 (94%) genes, where there was agreement between the platforms regarding statistical significance for 71 (76%) of 87 genes. There was a strong agreement between the two platforms as shown by comparisons of log2 fold differences of gene expression between tumor versus normal samples (R = 0.93) and by Bland-Altman analysis, where greater than 90% of expression values fell within the 95% limits of agreement.ConclusionOverall concordance of gene expression patterns based on correlations, statistical significance between tumor and normal ovary data, and fold changes was consistent between the Ziplex and Affymetrix platforms. The reproducibility and ease-of-use of the technology suggests that the Ziplex array is a suitable platform for translational research.

[1]  R. Bernards,et al.  Enabling personalized cancer medicine through analysis of gene-expression patterns , 2008, Nature.

[2]  Anne-Marie Mes-Masson,et al.  Signature of a silent killer: expression profiling in epithelial ovarian cancer , 2004, Expert review of molecular diagnostics.

[3]  Anil Potti,et al.  An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  V. Livolsi,et al.  Gene expression profiling of human ovarian tumours , 2006, British Journal of Cancer.

[5]  A. Mes-Masson,et al.  Reprogramming of the transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer , 2009, Molecular carcinogenesis.

[6]  A. Mes-Masson,et al.  Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes , 2008, Molecular carcinogenesis.

[7]  Crispin J. Miller,et al.  Cell Culture , 2010, Cell.

[8]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[9]  M. Moses,et al.  Ovarian cancer biomarkers: current options and future promise. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  T. Hudson,et al.  From gene profiling to diagnostic markers: IL‐18 and FGF‐2 complement CA125 as serum‐based markers in epithelial ovarian cancer , 2006, International journal of cancer.

[11]  E. D. de Vries,et al.  Molecular prognostic markers in ovarian cancer: toward patient‐tailored therapy , 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[12]  A. Mes-Masson,et al.  Construction of a chromosome 17 transcriptome in serous ovarian cancer identifies differentially expressed genes , 2007, International Journal of Gynecologic Cancer.

[13]  T. Hudson,et al.  Characterization of variability in large-scale gene expression data: implications for study design. , 2002, Genomics.

[14]  A. Ullrich,et al.  ErbB-3 predicts survival in ovarian cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Cannistra,et al.  Gene-expression profiling in epithelial ovarian cancer , 2008, Nature Clinical Practice Oncology.

[16]  K. Partheen,et al.  Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas , 2008, International journal of cancer.

[17]  T. Hudson,et al.  Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines. , 2007, International journal of oncology.

[18]  Anne-Marie Mes-Masson,et al.  Microarray analysis of gene expression mirrors the biology of an ovarian cancer model , 2001, Oncogene.

[19]  James J. Chen,et al.  Reproducibility of microarray data: a further analysis of microarray quality control (MAQC) data , 2007, BMC Bioinformatics.

[20]  Cherie Blenkiron,et al.  Identification of clinically relevant genes on chromosome 11 in a functional model of ovarian cancer tumor suppression. , 2003, Cancer research.

[21]  榎本 明美,et al.  What's going on 婦人科癌 Gene expression signature with independent prognostic significance in epithelial ovarian cancer. Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA, Cannistra SA. J Clin Oncol. 2004; 22: 4700-10. PMID: 15505275--上皮性卵巣癌における遺伝子発現特性は、独立した予後因子である , 2005 .

[22]  R. Agarwal,et al.  Expression profiling and individualisation of treatment for ovarian cancer. , 2006, Current opinion in pharmacology.

[23]  S. Minkin,et al.  High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. , 2005, Neoplasia.

[24]  S. Calza,et al.  Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. , 2006, Gynecologic oncology.

[25]  C. Le Page,et al.  BTF4/BTNA3.2 and GCS as Candidate mRNA Prognostic Markers in Epithelial Ovarian Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[26]  P. Collins,et al.  Performance comparison of one-color and two-color platforms within the Microarray Quality Control (MAQC) project , 2006, Nature Biotechnology.

[27]  Laurent Ozbun,et al.  A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. , 2008, Cancer research.

[28]  T. Hudson,et al.  Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines , 2003, Oncogene.

[29]  T. Hudson,et al.  Gene expression microarray analysis and genome databases facilitate the characterization of a chromosome 22 derived homogenously staining region , 2004, Molecular carcinogenesis.

[30]  Maqc Consortium The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements , 2006, Nature Biotechnology.

[31]  A. Mes-Masson,et al.  Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p , 2007, Oncogene.

[32]  Marie Joseph,et al.  Gene expression signature with independent prognostic significance in epithelial ovarian cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.